Key result
Ranolazine reduces ventricular arrhythmia incidence, including PVCs, VT, and VF.
Why the study?
Idiopathic dilated cardiomyopathy with electrical storm refractory to usual antiarrhythmic therapy presents a clinical challenge due to electrical instability and reentry mechanisms.
Systematic Review
May warrant trial in refractory electrical storm after standard therapy fails; leaves open confirmation in prospective studies.
A case of idiopathic dilated cardiomyopathy with an arrhythmic storm refractory to the usual antiarrhythmic therapy will be reported. The idiopathic structural heart disease of the patient is a vulnerable anatomic substrate in itself, for electrical instability and reentry mechanism, because of heterogeneous areas of scarred myocardium and low left ventricle ejection fraction. In this case, the ranolazine administration was safe and effective for the prevention of further electrical storms.
No takes yet. Share an insight, caveat, or question.
Enrico Vizzardi (2013) conducted a systematic review in Ventricular arrhythmias. Ranolazine vs. Placebo or standard care was evaluated on Incidence of ventricular arrhythmias (including PVCs, VT, VF, and ICD therapies). Ranolazine appears to have a beneficial effect in reducing the incidence of ventricular arrhythmias, including premature ventricular complexes, ventricular tachycardia, and ventricular fibrillation.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: